Table 6

Antitumor activity

Dose level (mg/m2)Tumor typeNo. of evaluable patientsNo. of respondersPrevious treatment
Days 1, 8, 15 q 28 days
 40Breast31 PRDoxa × 4, CMF × 6
Primary unknown11 PRMIC× 4, ECarboF × 2
 50Breast41 PRDox × 4, CMF × 6
1 PRDox × 4, CMF × 8
NSCLC21 PRMIC × 3, MVP × 3
Pleura11 PRNone
Days 1, 8 q 21 days
 50Ovary1Unconfirmed CRbCarbo/paclitaxel × 6 twice
NSCLC31 PRCarbo/VBL × 2, gemcitabine × 2
PNU159548 × 2
1 PRGem/Cis × 2
Gem/Carbo × 1
Intrapericardial thiotepa
  • a Dox, doxorubicin; CMF, cyclophosphamide, methotrexate, 5fluorouracil; MIC, mitomycin C, ifosfamide, cisplatin; EcarboF, epirubicin, carboplatin, 5fluorouracil; MVP, mitomycin C, vimblastine, cisplatin; Carbo, carboplatin; Gem, gemcitabine; Cis, cisplatin; and VBL, vimblastine.

  • b Confirmatory computed tomography scan not repeated later.